For the Quarter Ending December 2024
North America
During Q4 2024, Amlodipine Besylate prices in the USA exhibited dynamic shifts, driven by evolving market conditions. Prices surged in October due to heightened demand, fueled by Federal Reserve rate cuts that bolstered consumer confidence. Prolonged port congestion, labor strikes, and fears of tariff hikes under President-elect Donald Trump disrupted supply chains, exacerbating supply-demand imbalances and driving prices upward.
In November, prices slightly declined as demand softened amidst inflationary pressures and high interest rates. The appreciation of the U.S. dollar reduced import costs, while the resolution of the ILA strike eased logistics. These factors, combined with healthy inventories, allowed suppliers to lower prices, passing on savings to consumers.
By December, Amlodipine Besylate prices fell further due to dampened consumer confidence, seasonal demand slowdowns, and proactive inventory buildup ahead of potential January strikes and the Chinese Lunar New Year. Inflation concerns and tariff uncertainties prompted cautious buying, while ample supply and competitive pricing strategies added downward pressure. Overall, Q4 showcased a volatile market that ultimately trended downward. As of the end of Q4, Amlodipine Besylate was priced at USD 72,800 per metric ton (USP, FDA) CFR Los Angeles.
Asia Pacific
In Q4 2024, the Amlodipine Besylate market in China showcased a dynamic pricing trend influenced by varying economic and market factors. In October, prices rose significantly, driven by the resurgence of China's manufacturing sector following government stimulus measures. Increased domestic and export demand, coupled with monetary easing and a depreciated yuan, bolstered consumer confidence and external orders, enabling suppliers to raise prices.
However, this upward momentum reversed in November as high inventory levels, slowing domestic demand, and weak international orders, particularly from the USA and Europe, led to oversupply and cautious market sentiment. Falling crude oil prices further reduced operational costs, prompting manufacturers to lower prices to remain competitive.
In December, prices declined further due to subdued consumer demand amid China’s ongoing disinflation. Pharmaceutical companies and international buyers adjusted procurement strategies, contributing to weaker demand. Additionally, reduced foreign orders during the holiday season left suppliers with excess stock, forcing price cuts to clear inventories before year-end. Overall, Q4 reflected a shift from price gains in October to declines in the subsequent months due to fluctuating demand and market conditions. By the end of Q4, Amlodipine Besylate was priced at USD 70800 per metric ton in China.
Europe
In Q4 2024, Amlodipine Besylate prices in Germany exhibited contrasting trends across the months. October saw a significant price increase driven by improved business morale, bolstered by optimism around economic recovery and the European Central Bank’s third interest rate cut to 3.25%. This policy spurred spending and investment, while preemptive inventory buildup and supply chain challenges, including delays at Hamburg’s ports, added upward pressure.
However, November marked a downturn as weak end-sector demand and fading inflation concerns subdued price pressures. A sharp decline in consumer spending and retail performance in Germany, coupled with a 1.9% drop in energy prices, reduced operational costs and allowed suppliers to offer competitive rates.
The downward trend persisted into December due to weak demand from key sectors, cautious buyer behavior amid inflation concerns, and increased import costs due to the euro’s depreciation. Ample inventories and year-end stock clearance efforts further weighed on prices, while harsh winter conditions slowed consumer activity and logistics, exacerbating the decline. Overall, Q4 reflected a shift from initial optimism to economic caution, impacting price dynamics. By the end of Q4, Amlodipine Besylate was priced at USD 72610 per metric ton (USP, FDA) CFR Hamburg.
For the Quarter Ending September 2024
North America
During Q3 2024, the pricing landscape for Amlodipine Besylate in North America exhibited remarkable stability, marked by consistent market conditions throughout the quarter. Several key factors contributed to this stability, including steady demand from end-users and stable supply levels, resulting in a well-balanced equilibrium between supply and demand dynamics.
In the USA, where the most significant price fluctuations occurred, market trends reflected the broader North American environment. While the quarter recorded a slight percentage decrease in prices compared to the previous quarter, this adjustment was minor and did not indicate any drastic changes. Furthermore, a comparison between the first and second halves of the quarter revealed no substantial price variance, underscoring a period characterized by relative price stability.
As Q3 2024 drew to a close, Amlodipine Besylate was priced at USD 72,985 per metric ton (USP, FDA) CFR Los Angeles. This final price underscored the market's neutral position, reflecting a period where prices remained relatively stable throughout the quarter. Such consistency reinforces the overall trend of stability in the pricing environment for this pharmaceutical product, indicating a balanced interplay of supply and demand without significant fluctuations.
Asia Pacific
In Q3 2024, the APAC region witnessed a pronounced upward trend in Amlodipine Besylate prices, influenced by several key factors. Strong global demand, particularly from major markets, led to heightened precautionary orders, driving prices higher. Compounding this were supply chain disruptions, notably exacerbated by extreme weather events, which constrained supply levels and further fueled price increases. Despite facing challenges such as geopolitical uncertainties and the impact of tariffs, the market maintained a positive sentiment, buoyed by robust demand and favorable supply dynamics. China, in particular, experienced the most significant price fluctuations, mirroring broader trends across the region. The quarter highlighted a consistent upward movement in prices, with a notable 1% increase from the first half to the second half of the quarter. By the end of Q3 2024, Amlodipine Besylate was priced at USD 70,900 per metric ton in China, emphasizing the steady growth trajectory. Market participants actively focused on inventory management strategies to navigate these evolving market conditions. Overall, the quarter showcased a resilient market for Amlodipine Besylate in the APAC region, characterized by strong demand and effective supply management amidst various challenges.
Europe
In Q3 2024, the pricing trend for Amlodipine Besylate in Europe displayed a marked increase, particularly in Germany, where the most significant price changes occurred. Several critical factors contributed to this upward movement in market prices. Firstly, sustained high demand from end-users, along with improving economic conditions and declining inflation rates, created a solid foundation for price growth. Additionally, disruptions in shipping routes, especially due to the ongoing Red Sea crisis, prompted retailers to expedite their inventory replenishment, further fueling price increases. This environment fostered a positive market sentiment, with buyers increasing their purchasing activities to secure adequate inventory levels. While there was a slight decline in prices compared to the previous quarter, the overall trend for the quarter showed a 1% increase in prices from the first half to the second half. By the end of Q3 2024, Amlodipine Besylate was priced at USD 72,725 per metric ton (USP, FDA) CFR Hamburg in Germany, underscoring the upward trajectory in pricing during this period. Overall, the quarter illustrated a robust market for Amlodipine Besylate in Europe, driven by strong demand and proactive inventory management amidst various challenges.
For the Quarter Ending June 2024
North America
In Q2 2024, the North American market for Amlodipine besylate exhibited a mixed trajectory due to a complex interplay of factors shaping the pharmaceutical landscape. The USA experienced the most significant price fluctuations, with an unstable pricing environment throughout the quarter. Prices increased in April and May but decreased in June, influenced by demand dynamics, inventory levels, and global trade activity.
Initially, prices rose due to escalating domestic demand. Consumers, undeterred by cost fatigue, showed a willingness to spend, as evidenced by stronger retail sales, which boosted demand for Amlodipine besylate. Additionally, shipping challenges in the Red Sea region necessitated longer voyages and increased sailing speeds to counter delays. These adjustments led to higher fuel costs and elevated charter rates, while operational bottlenecks further strained shipping capacity, contributing to the price hikes.
However, by the end of the quarter, prices declined due to a downturn in business sentiment, creating economic uncertainty. This lack of confidence affected the pharmaceutical and healthcare industries, resulting in subdued demand for Amlodipine besylate. The quarter concluded with Amlodipine besylate prices at USD 72,100 per metric ton CFR Los Angeles, reflecting a persistently negative pricing environment.
Asia Pacific
In Q2 2024, the pricing landscape for Amlodipine besylate in the APAC region demonstrated a mixed trajectory influenced by various factors. Initially, prices rose due to increased market confidence compared to the previous month. The manufacturing sector continued to expand, driven by a surge in both domestic and international demand, which facilitated a swift acceleration in output growth. Manufacturers responded to this heightened demand by ramping up production levels to capitalize on the influx of new orders. However, prices declined toward the end of the quarter due to an oversupply situation. Increased manufacturing capacities outpaced existing demand, leading to a surplus. Additionally, lower production costs, driven by declining raw material prices and reduced transportation expenses, allowed manufacturers to adjust their pricing strategies downward. External demand remained sluggish as key export markets faced high interest rates, impacting consumer spending on pharmaceutical products. Concluding the quarter, the price of Amlodipine Besylate (USP, FDA) FOB Shanghai stood at USD 70,000 per metric ton, reflecting a stable pricing environment amidst the fluctuating market conditions.
Europe
In Q2 2024, the pricing landscape for Amlodipine besylate in Europe demonstrated a mixed trajectory influenced by several factors. Initially, prices rose as consumer spending increased, leading to higher demand for Amlodipine besylate. This optimistic economic climate was accompanied by elevated supply chain costs, driven by rising wages and high energy prices, which pushed up the cost of goods. However, by June, prices began to decline due to sluggish consumer demand, an overstocked market, and falling freight rates. The economic downturn, combined with reduced illness occurrences associated with warmer weather, further diminished demand. The central bank's decision to maintain unchanged interest rates also added financial pressure on consumers, suppressing purchasing activity. Despite occasional disruptions in the global supply chain, such as port congestion in Asia and North Europe and adverse weather conditions, there was some relief from easing geopolitical tensions and seasonal spikes in cargo volumes. These factors collectively helped to reduce transportation costs, contributing to the further decline in prices. The quarter ended with Amlodipine Besylate (USP, FDA) CFR Hamburg in Germany priced at USD 71,780 per metric ton, reflecting a consistent downward trend throughout the quarter.
For the Quarter Ending March 2024
North America
During Q1 2024, the pricing dynamics of Amlodipine Besylate in the North America region, particularly in the USA, were influenced by a blend of factors. At the outset of the quarter, prices experienced a modest decrease, driven by weakened demand from downstream industries and ample supply in the market. This decline in demand was further exacerbated by the effects of inflation and the Federal Reserve's decision to maintain steady rates.
However, prices surged in the middle of the quarter due to an increase in demand from downstream industries, further straining the already tight supply conditions prevalent in the domestic market. Another significant factor contributing to this heightened demand was the imminent arrival of the spring festival in China, prompting market retailers and distributors to proactively seek replenishment of their inventories. Additionally, disruptions in key maritime routes, such as the Red Sea and Panama Canal, posed challenges for shippers importing Amlodipine Besylate into the US, further exacerbating supply constraints. Nevertheless, prices experienced a significant decline again in March due to a downturn in business sentiments, which has cast a shadow of uncertainty over the economy. This lack of confidence has translated into subdued demand from end-user pharmaceutical and healthcare industries, leading to a downward trajectory in Amlodipine Besylate prices.
Looking at the year-over-year comparison, the price of Amlodipine Besylate in Q1 2024 was lower than the same quarter last year, reflecting the overall decrease in pricing. The final price for Amlodipine Besylate (USP, FDA) CFR Los Angeles in the USA at the end of the quarter was USD 73500/MT.
Asia Pacific
In Q1 2024, the pricing dynamics of Amlodipine Besylate in the APAC region, particularly in China, displayed a nuanced pattern influenced by various factors. These factors encompassed domestic manufacturing activity, global economic conditions, and disruptions in the supply chain. At the beginning of the quarter, prices experienced a slight decline as diminished demand from downstream sectors had a negative impact on the market. The manufacturing environment in China faced challenges, characterized by a slow domestic recovery and subdued external demand. Midway through the quarter, prices surged due to constrained inventories serving as a primary catalyst. The Spring Festival resulted in the closure or reduced operation of numerous factories, disrupting production and causing a shortage in the market. This supply-demand imbalance naturally led to an increase in prices as buyers competed for the limited available stock. However, prices declined again in March despite an uptick in economic activity in China following an extended holiday period. This positive momentum was overshadowed by concerns surrounding inadequate domestic demand. In terms of year-over-year comparison, the pricing of Amlodipine Besylate in Q1 2024 remained relatively stable compared to the same quarter last year. However, there was a decline in pricing compared to the last quarter of 2023, reflecting the overall downward trend. The final quarter's price for Amlodipine Besylate (USP, FDA) FOB Shanghai in China was assessed at USD 70000/MT, indicating a stable pricing level.
Europe
In Q1 2024, the pricing dynamics of Amlodipine Besylate in the Europe region underwent fluctuations influenced by various factors. At the beginning of the quarter, prices experienced a slight decline, reflecting subdued consumer sentiments and concerns about the economy. This decline in demand from both the pharmaceutical and healthcare sectors contributed to the decrease in prices for Amlodipine Besylate. However, prices surged in the middle of the quarter due to several factors, including rising consumer demand, logistical challenges, and limited inventories within the domestic market. Disruptions in shipping and logistics, typical during the Spring festival in China, led to delays and increased transportation expenses. These additional costs were passed on to buyers, contributing to the upward trend of Amlodipine Besylate prices. Nevertheless, prices experienced a significant decline again in March as the market grappled with persistently poor performance in new industrial orders. This was characterized by inadequate domestic demand juxtaposed against a relatively high backlog, further contributing to the downward trajectory of prices for Amlodipine Besylate in the Europe region. However, compared to the last quarter of 2023, there was a slight decrease in prices. Finally, the final quarter's price for Amlodipine Besylate (USP, FDA) CFR Hamburg in Germany was reported as USD 72150/MT.
